AveXis, the gene therapy biotech Novartis snapped up for $8.7 billion, will build a new manufacturing plant to produce its specialized therapies.
Johnson & Johnson opened a window into its eye health portfolio this week with the debut of a new corporate site.
Samsung BioLogics is well on its way to becoming the world's largest contract manufacturer.
Social media can be scary. But Alimera Sciences is convinced that with fastidious prep—and plenty of it—pharma companies should have nothing to fear.
The list the FDA published last week is not likely to cause broader damage to the reputations of companies named, experts say.
Pfizer is counting on some later-stage shots to carry the torch after its blockbuster Prevnar slows down. But it's stocking its early pipeline, too.
A jury today found a former exec of mail order pharmacy Philidor and a former Valeant Pharmaceuticals exec guilty of defrauding the drugmaker.
With new nods for Pfizer’s Xeljanz and AbbVie’s upadacitinib coming, makers of anti-inflammatory drugs will be feeling the heat from JAK inhibitors.
After pharma suffered an unexpected loss in this year's budget deal, the industry sees an opportunity to get some relief.
Former Novartis CEO Joe Jimenez was set to join the board of a leading hedge fund, but the plans are now on hold, WSJ reports.
Dova and its brand-new Doptelet could soon face off against Shionogi’s lusutrombopag, set for an FDA decision in August
.png?W7eRyp0Dx1zchvDVzNAu8fcM3SiLxl4I&itok=U8fEA8qf)
